Annual Report

Overview

The report describes FY2024 as a year of transformation, with continued clinical development of paxalisib and EVT801 across multiple cancer indications. It records an exclusive Sovargen licensing agreement with a US$1.5M upfront payment and up to $19M in potential milestones. The company also presents a developing ESG program integrating ESG risk into business strategy and reports that its compassionate-use program has treated over 40 patients in seven countries since 2018.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 30 June 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services